• *** Important Alert *** Beware of fraudulent messages or websites — only trust communications from @eacs-conference.com, @eacsociety.org, and our official partners: K.I.T. Group, Flugbörse, ACS Audiovisual, and Documedias.

abstract categories

  • Antiretroviral drugs (preclinical)
  • HIV cure and reservoirs
  • HIV diagnostics
  • Immunology
  • Virology
  • Pathogenesis and immunopathogenesis
  • Vaccines and immune-based therapies
  • Virus evolution and phylodynamic studies
  • AI for HIV prevention, diagnostics, and treatment
  • AI, big data, and digital innovation for the HIV response
  • Host genomics
  • Personalised medicine
  • Antiretroviral therapy: observational studies
  • Antiretroviral therapy: randomised clinical trials
  • Treatment in resource-constrained settings
  • Drug–drug interactions
  • HIV drug resistance
  • Pharmacology and pharmacogenomics
  • Toxicities
  • Sexually transmitted infections (STIs)
  • Tuberculosis and other opportunistic infections
  • Viral hepatitis
  • Vaccination
  • Mpox and emerging infectious diseases
  • Other co-infections, including COVID-19
  • Ageing and frailty
  • Co-morbidities
  • Neoplasia
  • Mental health and quality of life
  • Adolescents
  • Paediatrics
  • Pregnancy and breastfeeding
  • Antenatal screening
  • Access to and delivery of care
  • Cascade of care
  • Morbidity and mortality
  • Prevalence, incidence, and dynamics of HIV epidemics
  • Implementation science
  • HIV testing strategies, including co-testing
  • Pre-exposure prophylaxis (PrEP)
  • Post-exposure prophylaxis (PEP)
  • Treatment as prevention (TasP)
  • Lifestyle interventions
  • Migration
  • War and other conflicts
  • Behavioural science
  • Sex work
  • Substance use
  • Vulnerable and marginalised populations
  • Cisgender and transgender issues
  • Men who have sex with men (MSM)
Close

EACS 2025 Chatbot